泌尿外科门诊尿液分析中蛋白尿及其他异常的患病率
该横断面研究比较了泌尿外科门诊与普通门诊及肾癌患者尿液分析中蛋白尿的患病率,发现泌尿外科门诊蛋白尿比例高于非泌尿外科门诊,肾癌患者更高,且泌尿外科门诊中超过56%的患者至少存在一项尿液异常。
要点
- 泌尿外科门诊尿液分析蛋白尿患病率为18.6%,高于非泌尿外科门诊的8.6%。
- 肾癌患者蛋白尿比例更高,A2为17.9%,A3为3.8%。
- 泌尿外科门诊尿液分析中血尿、脓尿和菌尿常见,超过56%至少有一项异常。
核心结论
- 泌尿外科门诊尿液分析作为蛋白尿及其他状况的筛查工具价值似乎较高,超过56%的患者至少有一项异常。
- 泌尿外科门诊蛋白尿的人群风险为18.5%,高于非泌尿外科门诊观察到的水平。
- 肾癌患者似乎比一般泌尿外科患者更可能出现蛋白尿。
- 作者建议对泌尿外科患者进行尿液分析以识别蛋白尿。
研究设计与样本
- 横断面研究,纳入三个接受尿液分析的人群:普通门诊患者(n=20,334)、泌尿外科门诊患者(n=5023)和肾癌患者(n=1016)。
- 蛋白尿按肾脏病改善全球预后(KDIGO)指南分类:A1(<30 mg)、A2(30-300 mg)、A3(>300 mg)。
主要发现
- 在社区医疗系统中,8.6%的尿液分析检出蛋白尿(A2 8.2%;A3 0.4%)。
- 泌尿外科门诊进行的尿液分析中,18.6%有蛋白尿(A2 16.0%,A3 2.5%)(与非泌尿外科相比P < .0001)。
- 肾癌患者更可能有蛋白尿(A2 17.9%,A3 3.8%)。
- A3比例在泌尿外科和肾癌患者中显著高于其他门诊患者(各P < .0001),肾癌亚组与所有泌尿外科患者相比也显著更高(P < .0001)。
- 泌尿外科门诊尿液分析显微镜检查常见其他异常,包括血尿(20.9%)、脓尿(21.8%)和菌尿(3.1%)。
临床怎么用
- 作者建议对泌尿外科患者进行尿液分析以识别蛋白尿。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the prevalence of proteinuria in the urology clinic with other outpatient settings. Chronic kidney disease is classified according to cause, glomerular filtration rate, and proteinuria. Proteinuria may be more prevalent in patients with known chronic kidney disease, renal disorders (benign or malignant), or after urologic surgery. METHODS: A cross-sectional study of 3 populations undergoing urinalysis (UA) testing was carried out: general outpatients (n = 20,334), urology outpatients (n = 5023), and kidney cancer patients (n = 1016). Proteinuria was classified under Kidney Disease: Improving Global Outcomes guidelines: A1 (<30 mg), A2 (30-300 mg), and A3 (>300 mg). RESULTS: Proteinuria was detected throughout a community-based health system in 8.6% of UA (8.2%: A2; 0.4%: A3). In comparison, 18.6% of urology office-performed UA had proteinuria (16.0%: A2, 2.5%: A3) (P < .0001 vs non-urology). Kidney cancer patients were more likely to have proteinuria (17.9%: A2, 3.8%: A3). The proportion with A3 was significantly higher in urology and kidney cancer patients when compared with other outpatients (each P < .0001), and in the kidney cancer subgroup compared with all urology patients (P < .0001). Additional abnormalities were frequently present on microscopic analysis of UA in the urology clinic, including hematuria (20.9%), pyuria (21.8%), and bacteriuria (3.1%). CONCLUSION: The value of UA in the urology clinic as a screening test for proteinuria and other conditions appears high, with >56% having at least 1 abnormality. The population risk of proteinuria in the urology clinic is 18.5%, which is higher than that observed in non-urology clinics. Patients with kidney cancer appear more likely to have proteinuria than the average urology patient. We recommend evaluation of urology patients with UA to identify proteinuria.
引用
- Bezinque A, Noyes SL, Kirmiz S, et al. Prevalence of Proteinuria and Other Abnormalities in Urinalysis Performed in the Urology Clinic. Urology. 2017. PMID: 28212852. doi:10.1016/j.urology.2017.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。